Vemurafenib for BRAFV600E- positive metastatic papillary thyroid cancer

被引：3
|
作者：
Huillard, Olivier [1 ]
Tenenbaum, Florence [2 ]
Clerc, Jerome [2 ]
Goldwasser, Francois [1 ]
Groussin, Lionel [3 ]
机构：
[1] Paris Descartes Univ, Cochin Hosp, AP HP, Dept Med Oncol, F-75014 Paris, France
[2] Paris Descartes Univ, Cochin Hosp, AP HP, Dept Nucl Med, F-75014 Paris, France
[3] Paris Descartes Univ, Cochin Hosp, AP HP, Dept Endocrinol, F-75014 Paris, France
来源：
LANCET ONCOLOGY | 2016年 / 17卷 / 11期
关键词：
IODINE;
D O I：
10.1016/S1470-2045(16)30499-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：E468 / E468
页数：1
相关论文
共 50 条
  • [1] Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer Response
    Brose, Marcia S.
    Singh, Nathan
    LANCET ONCOLOGY, 2016, 17 (11): : E469 - E469
  • [2] Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAFV600E Mutation
    Kim, Kevin B.
    Cabanillas, Maria E.
    Lazar, Alexander J.
    Williams, Michelle D.
    Sanders, Deborah L.
    Ilagan, Joseph L.
    Nolop, Keith
    Lee, Richard J.
    Sherman, Steven I.
    THYROID, 2013, 23 (10) : 1277 - 1283
  • [3] Efficacy and Tolerability of Vemurafenib in Patients with BRAFV600E -Positive Papillary Thyroid Cancer: MD Anderson Cancer Center Off Label Experience
    Dadu, Ramona
    Shah, Komal
    Busaidy, Naifa L.
    Waguespack, Steven G.
    Habra, Mouhammad A.
    Ying, Anita K.
    Hu, Mimi I.
    Bassett, Roland
    Jimenez, Camilo
    Sherman, Steven I.
    Cabanillas, Maria E.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (01): : E77 - E81
  • [4] Identification of R-Spondin Gene Signature Predictive of Metastatic Progression in BRAFV600E-Positive Papillary Thyroid Cancer
    da Silva, Sabrina Daniela
    Morand, Gregoire B.
    Diesel, Luciana
    de Lima, Jefferson Muniz
    Bijian, Krikor
    Kailasam, Senthilkumar
    Lefebvre, Francois
    Bourque, Guillaume
    Hier, Michael
    Alaoui-Jamali, Moulay A.
    CELLS, 2023, 12 (01)
  • [5] Snail-1 Overexpression Correlates with Metastatic Phenotype in BRAFV600E Positive Papillary Thyroid Carcinoma
    Wieczorek-Szukala, Katarzyna
    Kopczynski, Janusz
    Kowalska, Aldona
    Lewinski, Andrzej
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09) : 1 - 11
  • [6] BRAFV600E Mutation and Papillary Thyroid Cancer: Chicken or Egg?
    Xing, Mingzhao
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (07): : 2295 - 2298
  • [7] Silencing FOXP2 reverses vemurafenib resistance in BRAFV600E mutant papillary thyroid cancer and melanoma cells
    Jiang, Suyuan
    Huang, Yuxin
    Li, Yuan
    Gu, Qin
    Jiang, Cuiping
    Tao, Xiaoming
    Sun, Jiao
    ENDOCRINE, 2023, 79 (01) : 86 - 97
  • [8] Silencing FOXP2 reverses vemurafenib resistance in BRAFV600E mutant papillary thyroid cancer and melanoma cells
    Suyuan Jiang
    Yuxin Huang
    Yuan Li
    Qin Gu
    Cuiping Jiang
    Xiaoming Tao
    Jiao Sun
    Endocrine, 2023, 79 : 86 - 97
  • [9] Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
    Brose, Marcia S.
    Cabanillas, Maria E.
    Cohen, Ezra E. W.
    Wirth, Lori J.
    Riehl, Todd
    Yue, Huibin
    Sherman, Steven I.
    Sherman, Eric J.
    LANCET ONCOLOGY, 2016, 17 (09): : 1272 - 1282
  • [10] BRAFV600E and Recurrence in Papillary Carcinoma Thyroid
    Kumari, N.
    George, N.
    Shukla, P.
    Vishwakarma, R.
    Agarwal, A.
    Krishnani, N.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06): : 827 - 827
12345